REHOVOT, ISRAEL and NORTH BRUNSWICK, NJ -- (MARKET WIRE) -- March 07, 2007 -- Rosetta Genomics Ltd. (NASDAQ: ROSG) announced today that it closed the sale of an additional 562,500 ordinary shares pursuant to the full exercise of the over-allotment option granted to the underwriters of its initial public offering. With the closing of the purchase of the over-allotment shares, a total of 4,312,500 ordinary shares were sold by Rosetta Genomics in the offering, resulting in gross proceeds of $30.2 million, before commissions and expenses, and net proceeds of $26.2 million.
